Marques MRC, et al. Nanomedicines - tiny particles and big challenges. Adv Drug Deliv Rev. 2019;151–152:23–43.
Nanomedicine and the COVID-19 vaccines. Nature Nanotechnology. 2020;15(12):963–963.
van der Meel R, Lammers T, Hennink WE. Cancer nanomedicines: oversold or underappreciated? Expert Opin Drug Deliv. 2017;14(1):1–5.
Soares S, et al. Nanomedicine: principles, properties, and regulatory issues. Front Chem. 2018;6(360).
Wolfram J, et al. Safety of Nanoparticles in Medicine. Curr Drug Targets. 2015;16(14):1671–81.
Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 2003;349(5):474–85.
Wu T, Tang M. Review of the effects of manufactured nanoparticles on mammalian target organs. J Appl Toxicol. 2018;38(1):25–40.
Zhao L, Zhang B. Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes. Sci Rep. 2017;7(1):44735.
Gabizon A, et al. Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol. 1994;33(7):779–86.
Hengge UR, et al. Fatal hepatic failure with liposomal doxorubicin. Lancet. 1993;341(8841):383–4.
Siegrist S, et al. Preclinical hazard evaluation strategy for nanomedicines. Nanotoxicology. 2019;13(1):73–99.
Etheridge ML, et al. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine. 2013;9(1):1–14.
Pelaz B, et al. Diverse applications of nanomedicine. ACS Nano. 2017;11(3):2313–81.
Collins SD, Yuen G, Tu T, et al. In vitro models of the liver: disease modeling, drug discovery and clinical applications., in Hepatocellular carcinoma. T.-P. JEE, Editor. 2009.
Fröhlich E. Comparison of conventional and advanced in vitro models in the toxicity testing of nanoparticles. Artif Cells Nanomed Biotechnol. 2018;46(sup2):1091–107.
Kumar V, Sharma N, Maitra SS. In vitro and in vivo toxicity assessment of nanoparticles. International Nano Letters. 2017;7(4):243–56.
Jensen C, Teng Y. Is it time to start transitioning from 2D to 3D cell culture?. Front Molecular Biosci. 2020:7(33).
Collins SD, et al. In vitro models of the liver: disease modeling, drug discovery and clinical applications, in Hepatocellular carcinoma. J.E.E. Tirnitz-Parker, Editor. 2019, Codon Publications Brisbane (AU). 2019;48–60.
Zhou Y, Shen JX, Lauschke VM. Comprehensive evaluation of organotypic and microphysiological liver models for prediction of drug-induced liver injury. 2019;10(1093).
Soldatow VY, et al. In vitro models for liver toxicity testing. Toxicol Res (Camb). 2013;2(1):23–39.
Abdel-Misih SR, Bloomston M. Liver anatomy. Surg Clin North Am. 2010;90(4):643–53.
Vigue J. Asklepios atlas of human anatomy. 2014.
Godoy P, et al. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol. 2013;87(8):1315–530.
Bacon BR, O'Grady JG, Di Bisceglie AM, Lake JR. Comprehensive clinical hepatology. Elsevier Ltd; 2006.
Portmann BC. Chapter 1 - Development and anatomy of the normal liver, in Comprehensive clinical hepatology (second edition), b.R. Bacon, et al., Editors. 2006, Mosby: Edinburgh. p. 1–15.
Sun T, et al. Engineered nanoparticles for drug delivery in cancer therapy. Angew Chem Int Ed Engl. 2014;53(46):12320–64.
Zhang Y-N, et al. Nanoparticle–liver interactions: cellular uptake and hepatobiliary elimination. J Control Release. 2016;240:332–48.
Gissen P, Arias IM. Structural and functional hepatocyte polarity and liver disease. J Hepatol. 2015;63(4):1023–37.
Soars MG, et al. The pivotal role of hepatocytes in drug discovery. Chem Biol Interact. 2007;168(1):2–15.
Zhou Z, Xu MJ, Gao B. Hepatocytes: a key cell type for innate immunity. Cell Mol Immunol. 2016;13(3):301–15.
Friedman LS. Diseases of the liver, seventh edition. Edited by L. Schiff and E. R. Schiff, 1,516 pp. Philadelphia: J.B. Lippincott, 1993. $195. Hepatology. 1994;19(3):797–798.
Haute DV, Berlin JM. Challenges in realizing selectivity for nanoparticle biodistribution and clearance: lessons from gold nanoparticles. Ther Deliv. 2017;8(9):763–74.
Saha K, et al. Regulation of macrophage recognition through the interplay of nanoparticle surface functionality and protein corona. ACS Nano. 2016;10(4):4421–30.
Smith DA, et al. Clearance in drug design. J Med Chem. 2019;62(5):2245–55.
Zhang YN, et al. Nanoparticle-liver interactions: cellular uptake and hepatobiliary elimination. J Control Release. 2016;240:332–48.
Samuelsson E, et al. Contribution of Kupffer cells to liposome accumulation in the liver. Colloids Surf, B. 2017;158:356–62.
Champion JA, Mitragotri S. Shape induced inhibition of phagocytosis of polymer particles. Pharm Res. 2009;26(1):244–9.
He C, et al. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials. 2010;31(13):3657–66.
Lunov O, et al. Modeling receptor-mediated endocytosis of polymer-functionalized iron oxide nanoparticles by human macrophages. Biomaterials. 2011;32(2):547–55.
Kamps JAAM, et al. Massive targeting of liposomes, surface-modified with anionized albumins, to hepatic endothelial cells. Proc Natl Acad Sci. 1997;94(21):11681–5.
Adrian JE, et al. Delivery of viral vectors to hepatic stellate cells in fibrotic livers using HVJ envelopes fused with targeted liposomes. J Drug Target. 2007;15(1):75–82.
Adrian JE, et al. Effects of a new bioactive lipid-based drug carrier on cultured hepatic stellate cells and liver fibrosis in bile duct-ligated rats. J Pharmacol Exp Ther. 2007;321(2):536–43.
Du S-L, et al. Cyclic Arg-Gly-Asp peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats. J Pharmacol Exp Ther. 2007;322(2):560–8.
Mezghrani O, et al. Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin. Int J Pharm. 2015;478(2):553–68.
Sato Y, et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol. 2008;26(4):431–42.
Akhter A, et al. Ligand density at the surface of a nanoparticle and different uptake mechanism: two important factors for successful siRNA delivery to liver endothelial cells. Int J Pharm. 2014;475(1):227–37.
Kren BT, et al. Nanocapsule-delivered Sleeping Beauty mediates therapeutic factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice. J Clin Invest. 2009;119(7):2086–99.
LeCluyse EL, Audus KL, Hochman JH. Formation of extensive canalicular networks by rat hepatocytes cultured in collagen-sandwich configuration. Am J Physiol. 1994;266(6 Pt 1):C1764–74.
Choi JM, et al. HepG2 cells as an in vitro model for evaluation of cytochrome P450 induction by xenobiotics. Arch Pharm Res. 2015;38(5):691–704.
Elizondo G, Medina-Diaz IM. Induction of CYP3A4 by 1alpha,25-dyhydroxyvitamin D3 in HepG2 cells. Life Sci. 2003;73(2):141–9.
Liu MC, et al. Tyrosine sulfation of proteins from the human hepatoma cell line HepG2. Proc Natl Acad Sci U S A. 1985;82(21):7160–4.
Vermeir M, et al. Cell-based models to study hepatic drug metabolism and enzyme induction in humans. Expert Opin Drug Metab Toxicol. 2005;1(1):75–90.
Kermanizadeh A, et al. An in vitro liver model - assessing oxidative stress and genotoxicity following exposure of hepatocytes to a panel of engineered nanomaterials. Part Fibre Toxicol. 2012;9(1):28.
Bandele OJ, et al. In vitro toxicity screening of chemical mixtures using HepG2/C3A cells. Food Chem Toxicol. 2012;50(5):1653–9.
Bale SS, et al. In vitro platforms for evaluating liver toxicity. Exp Biol Med (Maywood). 2014;239(9):1180–91.
Nibourg GA, et al. Proliferative human cell sources applied as biocomponent in bioartificial livers: a review. Expert Opin Biol Ther. 2012;12(7):905–21.
Guillouzo A, et al. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem Biol Interact. 2007;168(1):66–73.
Donato MT, et al. Cell lines: a tool for in vitro drug metabolism studies. Curr Drug Metab. 2008;9(1):1–11.
Gerets HH, et al. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol. 2012;28(2):69–87.
O’Brien PJ, et al. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch Toxicol. 2006;80(9):580–604.
Zeilinger K, et al. Cell sources for in vitro human liver cell culture models. Exp Biol Med (Maywood). 2016;241(15):1684–98.
Huang JR, et al. Liposomal irinotecan for treatment of colorectal cancer in a preclinical model. Cancers (Basel). 2019;11(3).
Wang P, et al. Evaluating cellular uptake of gold nanoparticles in HL-7702 and HepG2 cells for plasmonic photothermal therapy. Nanomedicine. 2018;13(18):2245–59.
Rathinaraj P, et al. Targeting and molecular imaging of HepG2 cells using surface-functionalized gold nanoparticles. J Nanopart Res. 2015;17(7):311.
Ashokkumar T, et al. Apoptosis in liver cancer (HepG2) cells induced by functionalized gold nanoparticles. Colloids Surf B Biointerfaces. 2014;123:549–56.
Namvar F, et al. Cytotoxic effect of magnetic iron oxide nanoparticles synthesized via seaweed aqueous extract. Int J Nanomedicine. 2014;9:2479–88.
Sulheim E, et al. Cytotoxicity of poly(alkyl cyanoacrylate) nanoparticles. Int J Mol Sci. 2017;18(11).
Sulheim E, et al. Cellular uptake and intracellular degradation of poly(alkyl cyanoacrylate) nanoparticles. J Nanobiotechnol. 2016;14(1):1.
Ramboer E, et al. Immortalized human hepatic cell lines for in vitro testing and research purposes. Methods Mol Biol. 2015;1250:53–76.
Prozialeck WC, et al. Epithelial barrier characteristics and expression of cell adhesion molecules in proximal tubule-derived cell lines commonly used for in vitro toxicity studies. Toxicol In Vitro. 2006;20(6):942–53.
Chamberlain LM, et al. Phenotypic non-equivalence of murine (monocyte-) macrophage cells in biomaterial and inflammatory models. J Biomed Mater Res A. 2009;88(4):858–71.
Milyavsky M, et al. Prolonged culture of telomerase-immortalized human fibroblasts leads to a premalignant phenotype. Cancer Res. 2003;63(21):7147–57.
Ramboer E, et al. Immortalized human hepatic cell lines for in vitro testing and research purposes. Methods in molecular biol (Clifton, N.J.). 2015;1250:53–76.
Ponsoda X, et al. Drug biotransformation by human hepatocytes. In vitro/in vivo metabolism by cells from the same donor. J Hepatol. 2001;34(1):19–25.
Gomez-Lechon MJ, et al. Human hepatocytes as a tool for studying toxicity and drug metabolism. Curr Drug Metab. 2003;4(4):292–312.
Gomez-Lechon MJ, et al. Human hepatocytes in primary culture: the choice to investigate drug metabolism in man. Curr Drug Metab. 2004;5(5):443–62.
Knobeloch D, et al. Human hepatocytes: isolation, culture, and quality procedures. Methods Mol Biol. 2012;806:99–120.
Rodriguez-Antona C, et al. Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica. 2002;32(6):505–20.
Hartung T, Daston G. Are in vitro tests suitable for regulatory use? Toxicol Sci. 2009;111(2):233–7.
Granitzny A, et al. Evaluation of a human in vitro hepatocyte-NPC co-culture model for the prediction of idiosyncratic drug-induced liver injury: A pilot study. Toxicol Rep. 2017;4:89–103.
Bale SS, et al. Isolation and co-culture of rat parenchymal and non-parenchymal liver cells to evaluate cellular interactions and response. Sci Rep. 2016;6:25329.
Ha S-W, et al. Chapter 4 - Applications of silica-based nanomaterials in dental and skeletal biology, in Nanobiomaterials in clinical dentistry (second edition), K. Subramani and W. Ahmed, Editors. 2019, Elsevier. p. 77–112.
Bale SS, et al. Long-term coculture strategies for primary hepatocytes and liver sinusoidal endothelial cells. Tissue Eng Part C Methods. 2015;21(4):413–22.
Ohno M, et al. Induction of drug-metabolizing enzymes by phenobarbital in layered co-culture of a human liver cell line and endothelial cells. Biol Pharm Bull. 2009;32(5):813–7.
Adams DH, et al. Mechanisms of immune-mediated liver injury. Toxicol Sci. 2010;115(2):307–21.
West MA, et al. Further characterization of Kupffer cell/macrophage-mediated alterations in hepatocyte protein synthesis. Surgery. 1986;100(2):416–23.
Yagi K, et al. Stimulation of liver functions in hierarchical co-culture of bone marrow cells and hepatocytes. Cytotechnology. 1998;26(1):5–12.
Ha S-W, et al. Applications of silica-based nanomaterials in dental and skeletal biology, in Nanobiomaterials in clinical dentistry, K. Subramani and W. Ahmed, Editors. Elsevier. 2019;77–112.
Edling Y, et al. Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009;23(7):1387–95.
Esch MB, et al. Body-on-a-chip simulation with gastrointestinal tract and liver tissues suggests that ingested nanoparticles have the potential to cause liver injury. Lab Chip. 2014;14(16):3081–92.
Duval K, et al. Modeling physiological events in 2D vs. 3D cell culture. Physiol (Bethesda). 2017;32(4):266–277.
Olsavsky Goyak KM, Laurenzana EM, Omiecinski CJ. Hepatocyte differentiation. Methods Mol Biol. 2010;640:115–38.
Kapalczynska M, et al. 2D and 3D cell cultures - a comparison of different types of cancer cell cultures. Arch Med Sci. 2018;14(4):910–9.
Gomez-Lechon MJ, et al. Long-term expression of differentiated functions in hepatocytes cultured in three-dimensional collagen matrix. J Cell Physiol. 1998;177(4):553–62.
Wells RG. The role of matrix stiffness in regulating cell behavior. Hepatology. 2008;47(4):1394–400.
Mitragotri S, et al. Drug delivery research for the future: expanding the nano horizons and beyond. J Control Release. 2017;246:183–4.
Bryda EC. The Mighty Mouse: the impact of rodents on advances in biomedical research. Mo Med. 2013;110(3):207–11.
Bahamonde J, et al. Gold nanoparticle toxicity in mice and rats: species differences. Toxicol Pathol. 2018;46(4):431–43.
Lu WL, et al. A pegylated liposomal platform: pharmacokinetics, pharmacodynamics, and toxicity in mice using doxorubicin as a model drug. J Pharmacol Sci. 2004;95(3):381–9.
Recordati C, et al. Tissue distribution and acute toxicity of silver after single intravenous administration in mice: nano-specific and size-dependent effects. Part Fibre Toxicol. 2016;13(1):12.
Chen Z, et al. Hepatotoxicity and the role of the gut-liver axis in rats after oral administration of titanium dioxide nanoparticles. Part Fibre Toxicol. 2019;16(1):48.
Tang H, et al. Liver toxicity assessments in rats following sub-chronic oral exposure to copper nanoparticles. Environ Sci Eur. 2019;31(1):30.
Khan HA, et al. Effects of naked gold nanoparticles on proinflammatory cytokines mRNA expression in rat liver and kidney. BioMed Res Int. 2013;2013:590730.
Abdelhalim MAK. Uptake of gold nanoparticles in several rat organs after intraperitoneal administration in vivo: a fluorescence study. BioMed Res Int. 2013;2013:353695.
Abdelhalim MAK, Abdelmottaleb Moussa SA. The gold nanoparticle size and exposure duration effect on the liver and kidney function of rats: in vivo. Saudi J Biol Sci. 2013;20(2):177–181.
Abdelhalim MAK, Mady MM. Liver uptake of gold nanoparticles after intraperitoneal administration in vivo: a fluorescence study. Lipids Health Dis. 2011;10(1):195.
Yahyaei B, et al. Effects of biologically produced gold nanoparticles: toxicity assessment in different rat organs after intraperitoneal injection. AMB Express. 2019;9(1):38.
Kozics K, et al. Pharmacokinetics, biodistribution, and biosafety of PEGylated gold nanoparticles in vivo. Nanomaterials (Basel). 2021;11(7).
Gaspar MM, et al. Targeted delivery of transferrin-conjugated liposomes to an orthotopic model of lung cancer in nude rats. J Aerosol Med Pulm Drug Deliv. 2012;25(6):310–8.
Le Magnen C, Dutta A, Abate-Shen C. Optimizing mouse models for precision cancer prevention. Nat Rev Cancer. 2016;16(3):187–96.
Begley CG, Ellis LM. Drug development: raise standards for preclinical cancer research. Nature. 2012;483(7391):531–3.
Cook N, Jodrell DI, Tuveson DA. Predictive in vivo animal models and translation to clinical trials. Drug Discov Today. 2012;17(5–6):253–60.
Seok J, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A. 2013;110(9):3507–12.
de Souza N. Mouse models challenged. Nat Methods. 2013;10(4):288–288.
Rangarajan A, Weinberg RA. Comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev Cancer. 2003;3(12):952–9.
Schachtschneider KM, et al. A validated, transitional and translational porcine model of hepatocellular carcinoma. Oncotarget. 2017;8(38):63620–34.
Ribitsch I, et al. Large animal models in regenerative medicine and tissue engineering: to do or not to do. Front Bioeng Biotechnol. 2020;8.
Andrasina T, et al. The accumulation and effects of liposomal doxorubicin in tissues treated by radiofrequency ablation and irreversible electroporation in liver: in vivo experimental study on porcine models. Cardiovasc Intervent Radiol. 2019;42(5):751–62.
Edge D, et al. Pharmacokinetics and bio-distribution of novel super paramagnetic iron oxide nanoparticles (SPIONs) in the anaesthetized pig. Clin Exp Pharmacol Physiol. 2016;43(3):319–26.
Ungureanu BS, et al. Iron oxide nanoparticles biodistribution in an experimental pig model - a new approach for delivery and imaging. Curr Health Sci J. 2015;41(4):333–8.
Kociova S, et al. Zinc phosphate-based nanoparticles as alternatives to zinc oxide in diet of weaned piglets. Journal of Animal Science and Biotechnology. 2020;11(1):59.
Saleh T, et al. Silver nanoparticles improve structural stability and biocompatibility of decellularized porcine liver. Artificial Cells, Nanomedicine, and Biotechnology. 2018;46(sup2):273–84.
Hannon G, et al. Immunotoxicity considerations for next generation cancer nanomedicines. Advanced Science. 2019;6(19):1900133.
Szebeni J, et al. Roadmap and strategy for overcoming infusion reactions to nanomedicines. Nat Nanotechnol. 2018;13(12):1100–8.
Vu MN, et al. Current and future nanoparticle vaccines for COVID-19. eBioMedicine. 2021;74:103699.
Sieber S, et al. Zebrafish as a preclinical in vivo screening model for nanomedicines. Adv Drug Deliv Rev. 2019;151–152:152–68.
Rennekamp AJ, Peterson RT. 15 years of zebrafish chemical screening. Curr Opin Chem Biol. 2015;24:58–70.
Peterson RT, et al. Small molecule developmental screens reveal the logic and timing of vertebrate development. Proc Natl Acad Sci U S A. 2000;97(24):12965–9.
Sieber S, et al. Zebrafish as an early stage screening tool to study the systemic circulation of nanoparticulate drug delivery systems in vivo. J Control Release. 2017;264:180–91.
EC. Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2020 on the Protection of Animals Used for Scientific Purposes. 2010.
Goldsmith P. Zebrafish as a pharmacological tool: the how, why and when. Curr Opin Pharmacol. 2004;4(5):504–12.
Menke AL, et al. Normal anatomy and histology of the adult zebrafish. 2011;39(5):759–75.
Jung HM, et al. Development of the larval lymphatic system in zebrafish. Development. 2017;144(11):2070–81.
Chen AT, Zon LI. Zebrafish blood stem cells. J Cell Biochem. 2009;108(1):35–42.
Trede NS, et al. The use of zebrafish to understand immunity. Immunity. 2004;20(4):367–79.
Isogai S, Horiguchi M, Weinstein BM. The vascular anatomy of the developing zebrafish: an atlas of embryonic and early larval development. Dev Biol. 2001;230(2):278–301.
Chu J, Sadler KC. New school in liver development: lessons from zebrafish. Hepatol (Baltimore, Md.). 2009;50(5):1656–1663.
Howe K, et al. The zebrafish reference genome sequence and its relationship to the human genome. Nature. 2013;496(7446):498–503.
Vibe CB, et al. Thioridazine in PLGA nanoparticles reduces toxicity and improves rifampicin therapy against mycobacterial infection in zebrafish. Nanotoxicology. 2016;10(6):680–8.
Peng K, et al. Cyclodextrin/dextran based drug carriers for a controlled release of hydrophobic drugs in zebrafish embryos. Soft Matter. 2010;6(16):3778–83.
Yan H, et al. Functional mesoporous silica nanoparticles for photothermal-controlled drug delivery in vivo. 2012;51(33):8373–7.
Hason M, Bartůněk P. Zebrafish models of cancer-new insights on modeling human cancer in a non-mammalian vertebrate. Genes (Basel). 2019;10(11).
Holbech H, et al. Detection of endocrine disrupters: evaluation of a fish sexual development test (FSDT). Comp Biochem Physiol C Toxicol Pharmacol. 2006;144(1):57–66.
Fomchenko EI, Holland EC. Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res. 2006;12(18):5288–97.
Huff J, Jacobson MF, Davis DL. The limits of two-year bioassay exposure regimens for identifying chemical carcinogens. Environ Health Perspect. 2008;116(11):1439–42.
Van Norman GA. Limitations of animal studies for predicting toxicity in clinical trials: is it time to rethink our current approach? JACC Basic Transl Sci. 2019;4(7):845–54.
Van Norman GA. Drugs, devices, and the FDA: Part 1: An overview of approval processes for drugs. JACC: Basic to Translational Sci. 2016;1(3):170–179.
Shanks N, Greek R, Greek J. Are animal models predictive for humans? Philosophy, ethics, and humanities in medicine : PEHM. 2009;4:2–2.
Greek R, Menache A. Systematic reviews of animal models: methodology versus epistemology. Int J Med Sci. 2013;10(3):206–21.
Hackam DG, Redelmeier DA. Translation of research evidence from animals to humans. JAMA. 2006;296(14):1731–2.
Perel P, et al. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ. 2007;334(7586):197.
Olson H, et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol. 2000;32(1):56–67.
Pound P, et al. Where is the evidence that animal research benefits humans? BMJ. 2004;328(7438):514–7.
Bracken MB. Why animal studies are often poor predictors of human reactions to exposure. J R Soc Med. 2009;102(3):120–2.
Xu JJ, Diaz D, O’Brien PJ. Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. Chem Biol Interact. 2004;150(1):115–28.
McKenzie R, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med. 1995;333(17):1099–105.
Institute of Medicine Committee to Review the Fialuridine Clinical T. In Review of the fialuridine (FIAU) clinical trials, F.J. Manning and M. Swartz, Editors. National Academies Press (US): Washington (DC). 1995.
Attarwala H. TGN1412: from discovery to disaster. J Young Pharm. 2010;2(3):332–6.
Xu D, et al. Fialuridine induces acute liver failure in chimeric TK-NOG mice: a model for detecting hepatic drug toxicity prior to human testing. PLoS Med. 2014;11(4):e1001628.
Babai S, Auclert L, Le-Louët H. Safety data and withdrawal of hepatotoxic drugs. Therapie. 2018.
Villano JL, Mehta D, Radhakrishnan L. Abraxane induced life-threatening toxicities with metastatic breast cancer and hepatic insufficiency. Invest New Drugs. 2006;24(5):455–6.
Socinski M. Update on nanoparticle albumin-bound paclitaxel. Clin Adv Hematol Oncol. 2006;4(10):745–6.
Administration USFaD. Investigational new drug (IND) application. U.S. Food and Drug Administration. 2017.
Zhang D, et al. Preclinical experimental models of drug metabolism and disposition in drug discovery and development. Acta Pharmaceutica Sinica B. 2012;2(6):549–61.
Akhtar A. The flaws and human harms of animal experimentation. Camb Q Healthc Ethics. 2015;24(4):407–19.
Di Cristo L, et al. Towards the identification of an in vitro tool for assessing the biological behavior of aerosol supplied nanomaterials. Int J Environ Res Public Health. 2018;15(4).
Bregoli L, et al. Nanomedicine applied to translational oncology: a future perspective on cancer treatment. Nanomedicine. 2016;12(1):81–103.
Movia D, et al. A safe-by-design approach to the development of gold nanoboxes as carriers for internalization into cancer cells. Biomaterials. 2014;35(9):2543–57.
Movia D, Bruni-Favier S, Prina-Mello A. In vitro alternatives to acute inhalation toxicity studies in animal models-a perspective. Frontiers in bioengineering and biotechnology. 2020;8:549–549.
Movia D, Prina-Mello A. Preclinical development of orally inhaled drugs (OIDs)-are animal models predictive or shall we move towards in vitro non-animal models?. Animals (Basel). 2020;10(8).
Prina-Mello A, et al. Editorial: Use of 3D models in drug development and precision medicine - advances and outlook. Front Bioeng Biotechnol. 2021;9(137).
Prina-Mello DMaA. Nanotoxicity in cancer research: technical protocols and considerations for the use of 3D tumour spheroids, unraveling the safety profile of nanoscale particles and materials, in From biomedical to environmental applications. IntechOpen. 2017.
Alepee N, et al. State-of-the-art of 3D cultures (organs-on-a-chip) in safety testing and pathophysiology. Altex. 2014;31(4):441–77.
Fleddermann J, et al. Distribution of SiO2 nanoparticles in 3D liver microtissues. Int J Nanomedicine. 2019;14:1411–31.
Ozkan A, et al. In vitro vascularized liver and tumor tissue microenvironments on a chip for dynamic determination of nanoparticle transport and toxicity. Biotechnol Bioeng. 2019;116(5):1201–19.
Otieno MA, Gan J, Proctor W. Status and future of 3D cell culture in toxicity testing, in Drug-induced liver toxicity, M. Chen and Y. Will, Editors. Springer New York: New York, NY. 2018;249–261.
Duval K, et al. Modeling physiological events in 2D vs. 3D cell culture. Physiol (Bethesda, Md.). 2017;32(4):266–277.
Fang Y, Eglen RM. Three-dimensional cell cultures in drug discovery and development. SLAS Discov. 2017;22(5):456–72.
Deng J, et al. Engineered liver-on-a-chip platform to mimic liver functions and its biomedical applications: a review. Micromachines (Basel). 2019;10(10):676.
Dunn JC, Tompkins RG, Yarmush ML. Hepatocytes in collagen sandwich: evidence for transcriptional and translational regulation. J Cell Biol. 1992;116(4):1043–53.
Dunn JC, Tompkins RG, Yarmush ML. Long-term in vitro function of adult hepatocytes in a collagen sandwich configuration. Biotechnol Prog. 1991;7(3):237–45.
Dunn JC, et al. Hepatocyte function and extracellular matrix geometry: long-term culture in a sandwich configuration. FASEB J. 1989;3(2):174–7.
Molina-Jimenez F, et al. Matrigel-embedded 3D culture of Huh-7 cells as a hepatocyte-like polarized system to study hepatitis C virus cycle. Virology. 2012;425(1):31–9.
Swift B, Pfeifer ND, Brouwer KLR. Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity. Drug Metab Rev. 2010;42(3):446–71.
Liu X, et al. Partial maintenance of taurocholate uptake by adult rat hepatocytes cultured in a collagen sandwich configuration. Pharm Res. 1998;15(10):1533–9.
Bell CC, et al. Comparison of hepatic 2D sandwich cultures and 3D spheroids for long-term toxicity applications: a multicenter study. Toxicological sciences : an official journal of the Society of Toxicology. 2018;162(2):655–66.
Ruoss M, et al. A standardized collagen-based scaffold improves human hepatocyte shipment and allows metabolic studies over 10 days. Bioengineering (Basel). 2018;5(4):86.
Lee J, et al. In vitro toxicity testing of nanoparticles in 3D cell culture. Small. 2009;5(10):1213–21.
Haldar S, Lahiri D, Roy P. Chapter 5 - 3D print technology for cell culturing, in 3D printing technology in nanomedicine, N. Ahmad, P. Gopinath, and R. Dutta, Editors. Elsevier. 2019;83–114.
Chang R, et al. Biofabrication of a three-dimensional liver micro-organ as an in vitro drug metabolism model. Biofabrication. 2010;2(4):045004.
Ma X, et al. Deterministically patterned biomimetic human iPSC-derived hepatic model via rapid 3D bioprinting. Proc Natl Acad Sci U S A. 2016;113(8):2206–11.
Nguyen AH, et al. MMP-mediated mesenchymal morphogenesis of pluripotent stem cell aggregates stimulated by gelatin methacrylate microparticle incorporation. Biomaterials. 2016;76:66–75.
Nguyen DG, et al. Bioprinted 3D primary liver tissues allow assessment of organ-level response to clinical drug induced toxicity in vitro. PLoS One. 2016;11(7):e0158674.
Pampaloni F, Stelzer E. Three-dimensional cell cultures in toxicology. Biotechnol Genet Eng Rev. 2010;26:117–38.
Wong SF, et al. Concave microwell based size-controllable hepatosphere as a three-dimensional liver tissue model. Biomaterials. 2011;32(32):8087–96.
Friedrich J, et al. Spheroid-based drug screen: considerations and practical approach. Nat Protoc. 2009;4(3):309–24.
Foty R. A simple hanging drop cell culture protocol for generation of 3D spheroids. Journal of visualized experiments : JoVE. 2011;51:2720.
Achilli T-M, Meyer J, Morgan JR. Advances in the formation, use and understanding of multi-cellular spheroids. Expert Opin Biol Ther. 2012;12(10):1347–60.
Otsuka H, et al. Micropatterned co-culture of hepatocyte spheroids layered on non-parenchymal cells to understand heterotypic cellular interactions. Sci Technol Adv Mater. 2013;14(6):065003–065003.
Edmondson R, et al. Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. Assay Drug Dev Technol. 2014;12(4):207–18.
Chang TT, Hughes-Fulford M. Monolayer and spheroid culture of human liver hepatocellular carcinoma cell line cells demonstrate distinct global gene expression patterns and functional phenotypes. Tissue Eng Part A. 2009;15(3):559–67.
Fey SJ, Wrzesinski K. Determination of drug toxicity using 3D spheroids constructed from an immortal human hepatocyte cell line. Toxicol Sci. 2012;127(2):403–11.
Vorrink SU, et al. Prediction of drug-induced hepatotoxicity using long-term stable primary hepatic 3D spheroid cultures in chemically defined conditions. Toxicol Sci. 2018;163(2):655–65.
Messner S, et al. Multi-cell type human liver microtissues for hepatotoxicity testing. Arch Toxicol. 2013;87(1):209–13.
Tostoes RM, et al. Human liver cell spheroids in extended perfusion bioreactor culture for repeated-dose drug testing. Hepatology. 2012;55(4):1227–36.
Peshwa MV, et al. Mechanistics of formation and ultrastructural evaluation of hepatocyte spheroids. In Vitro Cell Dev Biol Anim. 1996;32(4):197–203.
Riccalton-Banks L, et al. Long-term culture of functional liver tissue: three-dimensional coculture of primary hepatocytes and stellate cells. Tissue Eng. 2003;9(3):401–10.
Ramaiahgari SC, et al. A 3D in vitro model of differentiated HepG2 cell spheroids with improved liver-like properties for repeated dose high-throughput toxicity studies. Arch Toxicol. 2014;88(5):1083–95.
Elje E, et al. Hepato(geno)toxicity assessment of nanoparticles in a HepG2 liver spheroid model. Nanomaterials (Basel). 2020;10(3).
Dubiak-Szepietowska M, et al. Development of complex-shaped liver multicellular spheroids as a human-based model for nanoparticle toxicity assessment in vitro. Toxicol Appl Pharmacol. 2016;294:78–85.
Mikhail AS, Eetezadi S, Allen C. Multicellular tumor spheroids for evaluation of cytotoxicity and tumor growth inhibitory effects of nanomedicines in vitro: a comparison of docetaxel-loaded block copolymer micelles and Taxotere(R). PLoS One. 2013;8(4):e62630.
Huch M, et al. Long-term culture of genome-stable bipotent stem cells from adult human liver. Cell. 2015;160(1–2):299–312.
Prior N, Inacio P, Huch M. Liver organoids: from basic research to therapeutic applications. Gut. 2019;68(12):2228–37.
Akbari S, et al. Next-generation liver medicine using organoid models. Front Cell Dev Biol. 2019;7:345.
Palazzolo S, et al. An effective multi-stage liposomal DNA origami nanosystem for in vivo cancer therapy. Cancers (Basel). 2019;11(12).
de Graaf IA, et al. Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies. Nat Protoc. 2010;5(9):1540–51.
Palma E, Doornebal EJ, Chokshi S. Precision-cut liver slices: a versatile tool to advance liver research. Hepatol Int. 2019;13(1):51–7.
Wu X, et al. Precision-cut human liver slice cultures as an immunological platform. J Immunol Methods. 2018;455:71–9.
Palma E, Doornebal EJ, Chokshi S. Precision-cut liver slices: a versatile tool to advance liver research. Hep Intl. 2019;13(1):51–7.
Olinga P, et al. Rat liver slices as a tool to study LPS-induced inflammatory response in the liver. J Hepatol. 2001;35(2):187–94.
Dragoni S, et al. Gold nanoparticles uptake and cytotoxicity assessed on rat liver precision-cut slices. toxicological Sciences. 2012;128(1):186–197.
Hui AY, Friedman SL. Molecular basis of hepatic fibrosis. Expert Rev Mol Med. 2003;5(5):1–23.
Bartucci R, et al. Time-resolved quantification of nanoparticle uptake, distribution, and impact in precision-cut liver slices. Small. 2020;16(21):1906523.
van Midwoud PM, et al. A microfluidic approach for in vitro assessment of interorgan interactions in drug metabolism using intestinal and liver slices. Lab Chip. 2010;10(20):2778–86.
Vaira V, et al. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc Natl Acad Sci. 2010;107(18):8352–6.
Hattersley SM, Greenman J, Haswell SJ. Study of ethanol induced toxicity in liver explants using microfluidic devices. Biomed Microdevices. 2011;13(6):1005–14.
Freeman AE, Hoffman RM. In vivo-like growth of human tumors in vitro. Proc Natl Acad Sci U S A. 1986;83(8):2694–8.
Vaira V, et al. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc Natl Acad Sci U S A. 2010;107(18):8352–6.
Piera T. Organ culture model of liver for the study of cancer treatment for hepatocellular carcinoma. Cancer Res J. 2016;4:37.
Nath S, Devi GR. Three-dimensional culture systems in cancer research: focus on tumor spheroid model. Pharmacol Ther. 2016;163:94–108.
Hassan S, et al. Liver-on-a-chip models of fatty liver disease. Hepatology. 2020;71(2):733–40.
Toh YC, et al. A microfluidic 3D hepatocyte chip for drug toxicity testing. Lab Chip. 2009;9(14):2026–35.
Filippi C, et al. Improvement of C3A cell metabolism for usage in bioartificial liver support systems. J Hepatol. 2004;41(4):599–605.
Gebhardt R, Mecke D. Perifused monolayer cultures of rat hepatocytes as an improved in vitro system for studies on ureogenesis. Exp Cell Res. 1979;124(2):349–59.
Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32(8):760–72.
Gerlach JC, et al. Use of primary human liver cells originating from discarded grafts in a bioreactor for liver support therapy and the prospects of culturing adult liver stem cells in bioreactors: a morphologic study. Transplantation. 2003;76(5):781–6.
Li L, et al. A microfluidic 3D hepatocyte chip for hepatotoxicity testing of nanoparticles. Nanomedicine. 2019;14(16):2209–26.
Lu RXZ, Radisic M. Organ-on-a-chip platforms for evaluation of environmental nanoparticle toxicity. Bioactive Materials. 2021;6(9):2801–19.
Bhise NS, et al. Organ-on-a-chip platforms for studying drug delivery systems. J Control Release. 2014;190:82–93.
Gebhardt R, et al. New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures. Drug Metab Rev. 2003;35(2–3):145–213.
Li L, et al. A microfluidic 3D hepatocyte chip for hepatotoxicity testing of nanoparticles. Nanomedicine (Lond). 2019;14(16):2209–26.
Liu Y, Wang S, Wang Y. Patterned fibers embedded microfluidic chips based on PLA and PDMS for Ag nanoparticle safety testing. Polymers (Basel). 2016;8(11).
Wikswo JP. The relevance and potential roles of microphysiological systems in biology and medicine. Exp biol medicine (Maywood, N.J.). 2014;239(9):1061–1072.
Ashammakhi N, et al. Microphysiological systems: next generation systems for assessing toxicity and therapeutic effects of nanomaterials. 2020;4(1):1900589.
Zhang YS, Zhang Y-N, Zhang W. Cancer-on-a-chip systems at the frontier of nanomedicine. Drug Discovery Today. 2017;22(9):1392–9.
Lee SA, et al. Spheroid-based three-dimensional liver-on-a-chip to investigate hepatocyte-hepatic stellate cell interactions and flow effects. Lab Chip. 2013;13(18):3529–37.
Louhimies S. Directive 86/609/EEC on the protection of animals used for experimental and other scientific purposes. Altern Lab Anim. 2002;30(Suppl 2):217–9.
Neff EP. Printing cures: organovo advances with 3D-printed liver tissue. Lab Anim (NY). 2017;46(3):57.
Tolikas M, Antoniou A, Ingber DE. The Wyss Institute: a new model for medical technology innovation and translation across the academic-industrial interface. Bioeng Transl Med. 2017;2(3):247–57.
Conway GE, et al. Adaptation of the in vitro micronucleus assay for genotoxicity testing using 3D liver models supporting longer-term exposure durations. Mutagenesis. 2020.
Au - Llewellyn SV, et al. Advanced 3D liver models for in vitro genotoxicity testing following long-term nanomaterial exposure. JoVE. 2020(160):e61141.
Kermanizadeh A, et al. The importance of inter-individual Kupffer cell variability in the governance of hepatic toxicity in a 3D primary human liver microtissue model. Sci Rep. 2019;9(1):7295.
Barosova H, et al. An in vitro lung system to assess the proinflammatory hazard of carbon nanotube aerosols. Int J Mol Sci. 2020;21(15).
Au - Braakhuis HM, et al. An air-liquid interface bronchial epithelial model for realistic, repeated inhalation exposure to airborne particles for toxicity testing. JoVE. 2020(159):e61210.
Au - Barosova H, et al. Multicellular human alveolar model composed of epithelial cells and primary immune cells for hazard assessment. JoVE. 2020(159):e61090.
Ude VC, et al. Using 3D gastrointestinal tract in vitro models with microfold cells and mucus secreting ability to assess the hazard of copper oxide nanomaterials. J Nanobiotechnology. 2019;17(1):70.
Segovia-Miranda F, et al. Three-dimensional spatially resolved geometrical and functional models of human liver tissue reveal new aspects of NAFLD progression. Nat Med. 2019;25(12):1885–93.
Goulart E, et al. 3D bioprinting of liver spheroids derived from human induced pluripotent stem cells sustain liver function and viability in vitro. Biofabrication. 2019;12(1):015010.
Yang H, et al. Three-dimensional bioprinted hepatorganoids prolong survival of mice with liver failure. Gut. 2020;gutjnl-2019–319960.
Wang L, et al. Automated quantitative assessment of three-dimensional bioprinted hydrogel scaffolds using optical coherence tomography. Biomed Opt Express. 2016;7(3):894–910.
Kizawa H, et al. Scaffold-free 3D bio-printed human liver tissue stably maintains metabolic functions useful for drug discovery. Biochemistry and Biophysics Reports. 2017;10:186–91.
NCATS. https://ncats.nih.gov/pubs/features/3d-bioprinting. 2018; Available from: https://ncats.nih.gov/pubs/features/3d-bioprinting.
Livingston CA, Fabre KM, Tagle DA. Facilitating the commercialization and use of organ platforms generated by the microphysiological systems (Tissue Chip) program through public–private partnerships. Comput Struct Biotechnol J. 2016;14:207–10.
Kaiser J. Seven years later, NIH center that aims to speed drugs to market faces challenges. 2019 [cited 2022 04/01]; Available from: https://www.sciencemag.org/news/2019/09/seven-years-later-nih-center-aims-speed-drugs-market-faces-challenges.
Zhang YS, et al. 3D bioprinting for tissue and organ fabrication. Ann Biomed Eng. 2017;45(1):148–63.
Campbell KH, et al. Sheep cloned by nuclear transfer from a cultured cell line. Nature. 1996;380(6569):64–6.
Yue F, et al. A comparative encyclopedia of DNA elements in the mouse genome. Nature. 2014;515(7527):355–64.
Brownell L. A swifter way towards 3D-printed organs. 2019 [cited 2022 04/01]; Available from: https://wyss.harvard.edu/news/a-swifter-way-towards-3d-printed-organs/.
Huh D, et al. Reconstituting organ-level lung functions on a chip. Science. 2010;328(5986):1662–8.
Herland A, et al. Quantitative prediction of human pharmacokinetic responses to drugs via fluidically coupled vascularized organ chips. Nature Biomedical Engineering. 2020;4(4):421–36.